Michael Sardano Sells 5,000 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating) General Counsel Michael Sardano sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $14.13, for a total value of $70,650.00. Following the transaction, the general counsel now owns 49,519 shares in the company, valued at $699,703.47. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Sensus Healthcare Price Performance

SRTS opened at $14.80 on Friday. The firm has a market cap of $245.09 million, a price-to-earnings ratio of 9.80 and a beta of 0.77. Sensus Healthcare, Inc. has a 1 year low of $3.50 and a 1 year high of $15.25. The stock’s 50 day simple moving average is $12.18 and its 200 day simple moving average is $10.01.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. The firm had revenue of $12.08 million for the quarter, compared to analyst estimates of $10.28 million. Sensus Healthcare had a return on equity of 36.74% and a net margin of 61.26%. As a group, sell-side analysts anticipate that Sensus Healthcare, Inc. will post 0.77 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

A number of large investors have recently made changes to their positions in SRTS. Lazard Asset Management LLC bought a new stake in shares of Sensus Healthcare in the 2nd quarter worth approximately $49,000. Dorsey Wright & Associates bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $54,000. Brinker Capital Investments LLC bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $104,000. D.A. Davidson & CO. bought a new stake in shares of Sensus Healthcare in the 2nd quarter worth approximately $112,000. Finally, Jane Street Group LLC lifted its stake in shares of Sensus Healthcare by 29.9% in the 2nd quarter. Jane Street Group LLC now owns 17,167 shares of the company’s stock valued at $132,000 after purchasing an additional 3,948 shares during the period. 31.52% of the stock is currently owned by institutional investors.

About Sensus Healthcare

(Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Stories

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.